Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Thyroid Cancer
Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions
FDA Approvals, News & Updates
,
Thyroid Cancer
December 2020, Vol 11, No 6
On
December 1, 2020
, the FDA accelerated the approval of a new indication for pralsetinib (Gavreto; Blueprint Medicines), a
RET
kinase inhibitor, for the treatment of patients aged ≥12 years with advanced or metastatic medullary thyroid cancer and
RET
mutation who require systemic therapy or for patients with thyroid cancer and
RET
fusion who require systemic therapy and whose tumor is refractory to radioactive iodine, if radioactive iodine is appropriate.
Read Article
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
By
Yvette Florio Lane
FDA Approvals, News & Updates
,
In the News
,
Lung Cancer
,
Personalized Medicine
,
Thyroid Cancer
Web Exclusives
On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced
RET
fusion-positive non–small-cell lung cancer,
RET
-mutant medullary thyroid cancer, and
RET
fusion-positive thyroid cancer.
Read Article
Biology, Genetics Guide Diagnosis and Treatment of Thyroid Cancers
By
Charles Bankhead
Personalized Medicine
,
Thyroid Cancer
October 2016, Vol 7, No 9
Recent advances in the management of thyroid cancer have evolved directly from improved knowledge of the underlying genetics and molecular biology, an understanding that will continue to improve in the future, according to a recent review.
Read Article
SELECT: Lenvatinib Improves Outcomes as First-Line Treatment in Older Patients with Thyroid Cancer
By
Alice Goodman
Solid Tumors
,
Thyroid Cancer
September 2015, Vol 6, No 8
Chicago, IL—Lenvatinib (Lenvima) was approved by the FDA in February 2015 for the treatment of patients with advanced radioactive iodine (
131
I)-refractory differentiated thyroid cancer based on the SELECT trial results. Investigators looked at which patients will preferentially benefit from this oral tyrosine kinase inhibitor (TKI). At the 2015 American Society of Clinical Oncology meeting, 2 subgroup analyses of SELECT shed light on patient selection for treatment with lenvatinib.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma